Process Development and CMC: Small Models, Real Savings

While generative AI commands headlines across life sciences, process development and Chemistry, Manufacturing, and Controls (CMC) teams in biopharma often extract more immediate practical utility from modest, specialized computational tools. Physical bioreactor runs require substantial time, expensive raw materials, and dedicated analytical bandwidth. Because analytical turnaround times frequently extend optimization loops over several weeks, large neural network architectures are rarely suited to these data-sparse environments. Small, domain-informed models offer a more pragmatic approach to navigating tight experimental windows and complex physical constraints.

Small machine learning models, such as Gaussian process regressions, partial least squares, and constrained autoencoders, present targeted alternatives for bioprocessing. When deployed with clear operational intent and validated datasets, these approaches can help reduce physical experimental loads, assist real-time process monitoring, and support deviation root-cause investigations.

Reducing DoE Burdens with Surrogate Models

Traditional Design of Experiments (DoE) strategies remain central to defining a robust process design space. However, full-factorial or response-surface designs scale rapidly as operational parameters accumulate. Evaluating interactions across feed schedules, temperature profiles, pH setpoints, and dissolved oxygen levels can quickly generate an experimental matrix that exceeds available bench-top or pilot-scale bioreactor capacity.

Surrogate modeling uses historical run data and early experimental iterations to construct an approximate mathematical representation of the operational design space. Techniques such as Bayesian optimization paired with Gaussian processes evaluate existing parameter space and propose the next most informative conditions to test. Rather than filling out a rigid, high-density experimental grid, the algorithm identifies regions where parameter uncertainty remains high or where optimization gradients are steepest.

In practical application, process development teams evaluating surrogate modeling aim to map operational boundaries using fewer physical runs than standard response-surface methodologies require. This approach can conserve cell culture media, chromatography resins, and analytical testing capacity while helping teams establish design space boundaries within project timelines.

Soft Sensors: Turning Real-Time Signal into Quality Insight

A persistent operational challenge in upstream and downstream bioprocessing is the lag between physical sampling and off-line analytical testing. Assays for critical quality attributes, such as viable cell density, product titer, charge variants, and impurity profiles, often require hours or days to complete in analytical development laboratories.

Soft sensors are inferential software models designed to estimate unmeasured quality attributes from accessible, continuous process measurements. By continually reading online signals such as vessel pH, dissolved oxygen, off-gas composition, feed rates, and spectroscopic readings, a calibrated model provides real-time estimates of target quality metrics. Partial least squares regression or tree-based ensemble models trained on historical batch telemetry can estimate nutrient consumption or cell viability throughout a fed-batch process.

This continuous estimation allows operators to evaluate dynamic feed adjustments or harvest timing based on estimated biological state rather than fixed elapsed time. When properly calibrated against off-line reference assays, real-time inferential feedback offers the potential to narrow batch-to-batch variability before material proceeds to downstream purification steps.

Catching Deviations Before the Batch Fails

In clinical and commercial manufacturing, an unexpected out-of-trend batch triggers lengthy root-cause investigations and risks potential lot rejection. Traditional facility monitoring often relies on single-variable control limits, which can generate false alarms or fail to detect subtle, multi-parameter drift occurring across several process variables simultaneously.

Multivariate anomaly detection uses techniques such as Principal Component Analysis or sparse autoencoders applied to continuous time-series telemetry. Rather than assessing whether an individual parameter has breached a fixed boundary, these models monitor dynamic correlations across multiple process variables throughout the batch lifecycle. If multi-parameter relationships begin to deviate from the historical operating envelope, the model alerts engineers to an anomaly early in the run.

This early notification provides technical operations teams a broader window to investigate parameter shifts, evaluate feed rate adjustments, or address utility fluctuations before process boundaries are compromised.

Quality Unit Integration and Change Control Realities

A frequent friction point when introducing machine learning to CMC workflows is not mathematical complexity, but regulatory governance and quality oversight. Regulatory expectations vary according to the intended use of the tool, development stage, record-keeping requirements, and applicable regional guidelines, such as those published by the US FDA, EMA, or PMDA.

Software and modeling tools may support, but do not satisfy, regulatory compliance or GxP validation requirements on their own. Applicability and validation expectations depend heavily on how modeling data are captured and whether algorithm outputs directly inform regulatory filings or batch execution decisions. When a soft sensor or predictive model directly drives operational adjustments during clinical manufacturing or supports batch release decisions, it falls under formal quality management system oversight.

Process engineers should engage the Quality Unit early during project scoping. Algorithms intended for use within regulated environments typically require a frozen, deterministic state where model parameters do not update automatically on live production data without formal change evaluation. Adaptive models that continually re-train on live streaming data introduce unmanaged risks into change control frameworks. Every model update should be managed as a process change, supported by predefined re-validation criteria, drift detection protocols, and documented risk assessments governed by internal quality assurance procedures.

Scoping Your First Project: Where to Start

Successful deployment relies on choosing narrow, well-defined problems supported by structured historical data. Organizations often encounter unnecessary friction when attempting to construct a facility-wide digital twin before demonstrating utility on a single unit operation. A pragmatic starting point focuses on a well-understood step with clean historical data, such as seed-train expansion or primary capture chromatography.

When planning an initial project, engineering and quality teams should evaluate the following considerations, subject to internal quality management systems, site-specific SOPs, and cross-functional expert review:

• Define a specific operational challenge, such as yield variability or analytical lag times during harvest timing selection.
• Audit historical data quality across past batches to confirm that continuous time-series signals and off-line analytical labels are aligned and accurately timestamped.
• Define a clear operational baseline from historical runs against which model accuracy, resource utilization, and predictive performance can be measured.
• Develop and evaluate candidate algorithms in a non-regulated sandbox environment using simple, interpretable models before considering complex architectures.
• Establish explicit operational handoffs and safety limits, ensuring qualified human operators maintain direct oversight and decision-making authority over all process adjustments.

By deploying small, transparent models aligned with domain expertise and formal quality governance, bioprocessing groups can achieve practical operational efficiencies while maintaining alignment with internal quality standards.

How it works in practice

Process development models are usually small, trained on a few hundred runs rather than millions, and that is exactly why they work. Here is the generalized pattern.

• What data goes in. Historical batch records and DoE results: process parameters (temperature, pH, feed rate, agitation, hold times), raw-material lot attributes, and the in-process and release measurements that came out the other end. Where available, real-time sensor and spectroscopic traces are added.
• What the model predicts or ranks. A critical quality attribute or yield as a function of the process parameters — either as a surrogate for the process itself, or as a soft sensor estimating an offline measurement from signals available in real time.
• Technique or model family. Partial least squares and other multivariate methods remain the workhorse; gradient-boosted trees for tabular parameter-to-attribute relationships; Gaussian processes with Bayesian optimization to propose the next experiments in a DoE campaign.
• How it is trained or validated. Held out by batch and by campaign, not by row, since measurements within a batch are correlated. A soft sensor is validated against the offline assay it is meant to anticipate, across the operating range, before it informs anything.
• What the team does with the output. The model narrows the experimental space so a DoE runs in fewer experiments, or it gives operators an early read on where a batch is heading. Any change to a validated process still goes through change control.
• A representative example. Input: the current run's temperature, pH and feed profile at hour 96. Output: predicted titre with an uncertainty band, trending below the historical range. The team investigates while the batch is still running instead of learning about it at release.

Sources

1. ICH Quality Guidelines (Q8 Pharmaceutical Development, Q9 Quality Risk Management, Q10 Pharmaceutical Quality System) — International Council for Harmonization.
2. PAT — A Framework for Innovative Pharmaceutical Development, Manufacturing, and Quality Assurance — U.S. Food and Drug Administration.
3. General Principles of Software Validation — U.S. Food and Drug Administration.